XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1
STOCK-BASED COMPENSATION
 6 Months Ended
Jun. 30, 2024
STOCK-BASED COMPENSATION  
STOCK-BASED COMPENSATION

7.    STOCK-BASED COMPENSATION

The Company may issue stock-based compensation awards under the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan (as amended, the “2022 Plan”) or the Helius Medical Technologies, Inc. 2021 Inducement Plan (as amended, the “Inducement Plan”), as described more fully in the 2023 10-K. On January 1, 2023, pursuant to the automatic increase provision of the 2022 Plan, the number of shares authorized for issuance increased from 264,319 to 319,941. On May 30, 2024, the Board adopted a First Amendment (the “Amendment”) to the 2022 Plan. On June 27, 2024, at the annual meeting of stockholders, the stockholders of the Company approved the Amendment. Pursuant to the terms and conditions of the Amendment, the 2022 Plan was amended to increase the aggregate number of shares of Common Stock that may be issued under the 2022 Plan to 2,089,000 new shares with an automatic increase on January 1st of each year by an amount equal to 5% of the Fully Diluted Shares (as defined in the 2022 Plan) as of the last day of the preceding calendar year. As of June 30, 2024, the remaining shares available for grant were 1,846,187 under the 2022 Plan. On July 2, 2024, the Company approved an amendment to the Inducement Plan pursuant to which, the Inducement Plan was amended to increase the aggregate number of shares of Common Stock that may be issued under

the Inducement Plan to 150,000 new shares. As of July 2, 2024 there were 147,290 shares of common stock available for issuance under the Inducement Plan.

During the six months ended June 30, 2024, the Company did not grant any stock options or restricted stock units out of the 2022 Plan or the Inducement Plan.

As of June 30, 2024, there were an aggregate of 245,523 stock options outstanding with a weighted average exercise price of $76.29 per share and no unvested restricted stock units outstanding.

​

Total stock-based compensation expense was as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Three Months Ended

​

Six Months Ended

​

​

June 30, 

​

June 30, 

​

​

2024

​

2023

​

2024

​

2023

Cost of sales

​

$

5

​

$

5

​

$

9

​

$

9

Selling, general and administrative

​

 

298

​

 

339

​

​

628

​

​

659

Research and development

​

​

64

​

​

76

​

​

130

​

​

157

Total stock-based compensation expense

​

$

367

​

$

420

​

$

767

​

$

825

​

As of June 30, 2024, the total remaining unrecognized compensation expense related to nonvested stock options and restricted stock units was $1.7 million which will be amortized over the weighted-average remaining requisite service period of 0.8 years.